Please assess the completion status of the following clinical trial:

Trial Title: Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Males \& females, age ≥ 18 years (or minimum adult age as determined by local regulatory authorities)~2. Screening plasma HIV-1 RNA ≥ 5,000 copies/mL~3. CD4+ lymphocyte cell count ≥ 300 cells/mm3 and no documented count \< or = 250 cells/mm3~4. Has not taken any antiretroviral therapy (ART) w/in 12 wks of Early Screening Visit~5. Exclusive CCR5-tropic virus as determined by Trofile™ Assay at Early Screening Visit~6. Clinically normal or not clinically significant (NCS) resting electrocardiogram~7. Women of reproductive potential must have a negative serum pregnancy test at Late Screening Visit \& a negative urine pregnancy test w/in 72 hrs prior to first dose of study medication, \& be non-lactating. Male \& female subjects must agree not to participate in a conception process from Early Screening Visit through Day 59.~Exclusion Criteria:~1. CXCR4 tropic virus or dual/mixed tropic (R5X4) virus determined by the Trofile™ Assay.~2. Females who are pregnant, lactating or breastfeeding, or who plan to become pregnant during the study.~3. History of active hepatitis within the previous 24 wks~4. Prior use of any entry, attachment, CCR5 co-receptor or fusion inhibitor, including PRO 140, experimental or approved.~5. Any immunization or vaccination (including influenza vaccine) within 30 days prior to administration of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): PRO 140 for three single SC doses: Days 1, 8, and 15
- Arm 2 (Type: ACTIVE_COMPARATOR): PRO 140 for three single SC doses: Days 1, 8 and 15
- Arm 3 (Type: ACTIVE_COMPARATOR): PRO 140 for two single SC doses: Days 1 and 15 plus one SC dose of PBO at Day 8
- Arm 4 (Type: PLACEBO_COMPARATOR): PBO for three single SC doses: Days 1, 8 and 15

Based on this trial design, predict the completion outcome and termination type (if applicable).